Author:
Dias-Barbosa Carla,Silverberg Jonathan I.,Ständer Sonja,Rodriguez Danielle,Fofana Fatoumata,Filipenko Dina,Ulianov Liliana,Piketty Christophe,Puelles Jorge
Abstract
Abstract
Background
Patient-focused approaches to capturing day-to-day variability in sleep disturbance are needed to properly evaluate the sleep benefits of new treatments. Such approaches rely on patient-reported outcome (PRO) measures validated in the target patient population.
Methods
Using atopic dermatitis (AD) as an example of a disease in which sleep is commonly disturbed, we developed a strategy for measuring sleep disturbance in AD trials. In developing this strategy, we conducted a targeted literature review and held concept elicitation interviews with adolescents and adults with AD. We subsequently identified potentially suitable PRO measures and cognitively debriefed them. Finally, we evaluated their psychometric properties using data from phase 2b (NCT03100344) and phase 3 (NCT03985943 and NCT03989349) clinical trials.
Results
The literature review confirmed that sleep disturbance is a key impact of AD but failed to identify validated PRO measures for assessing fluctuations in sleep disturbance. Subsequent concept elicitation interviews confirmed the multidimensional nature of sleep disturbance in AD and supported use of a single-item measure to assess overall sleep disturbance severity, complemented by a diary to capture individual components of sleep disturbance. The single-item sleep disturbance numerical rating scale (SD NRS) and multi-item Subject Sleep Diary (SSD)—an AD-adapted version of the Consensus Sleep Diary—were identified as potentially suitable PRO measures. Cognitive debriefing of the SD NRS and SSD demonstrated their content validity and their understandability to patients. Psychometric analyses based on AD trial data showed that the SD NRS is a well-defined, reliable, and fit-for-purpose measure of sleep disturbance in adults with AD. Furthermore, the SD NRS correlated with many SSD sleep parameters, suggesting that most concepts from the SSD can be covered using the SD NRS.
Conclusions
Using these findings, we developed an approach for measuring sleep disturbance in AD trials. Subject to further research, the same approach could also be applied to future trials of other skin diseases where itch causes sleep disturbance.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. FDA (2022) Patient-focused drug development: Selecting, developing, or modifying fit-for-purpose clinical outcome assessments. U.S. Food and Drug Administration. Available via https://www.fda.gov/media/159500/download. Accessed 3 Oct 2022
2. Kapur S, Watson W, Carr S (2018) Atopic dermatitis. Allergy Asthma Clin Immunol 14:52. https://doi.org/10.1186/s13223-018-0281-6
3. Bender BG, Ballard R, Canono B, Murphy JR, Leung DY (2008) Disease severity, scratching, and sleep quality in patients with atopic dermatitis. J Am Acad Dermatol 58:415–420. https://doi.org/10.1016/j.jaad.2007.10.010
4. Jeon C, Yan D, Nakamura M, Sekhon S, Bhutani T, Berger T, Liao W (2017) Frequency and management of Sleep disturbance in adults with atopic dermatitis: a systematic review. Dermatol Ther (Heidelb) 7:349–364. https://doi.org/10.1007/s13555-017-0192-3
5. Li JC et al (2018) Sleep disturbance and sleep-related impairment in adults with atopic dermatitis: a cross-sectional study. Dermatitis 29:270–277. https://doi.org/10.1097/DER.0000000000000401